Inventor · disambiguated record
Yibin Zeng
Also filed as: ZENG YIBIN
66 granted patents·27 pending applications·612 citations·filing 2006–2025
99Inventor score
Top patents by PatentIndex Score
93 records- 0199US7884110B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2008·Granted Feb 8, 2011·41 cites·6 claims
- 0298US7622583B2Heteroaryl sulfonamides and CCR2CHEMOCENTRYX INC·Filed 2006·Granted Nov 24, 2009·106 cites·5 claims
- 0397US11266643B2Triaryl compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Mar 8, 2022·13 cites·32 claims
- 0497US10035768B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Jul 31, 2018·23 cites·10 claims
- 0597US9745312B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2016·Granted Aug 29, 2017·13 cites·19 claims
- 0697US9573897B2C5AR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Feb 21, 2017·24 cites·9 claims
- 0796US11713307B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Aug 1, 2023·8 cites·28 claims
- 0896US11478460B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·34 claims
- 0996US11026935B2Free base crystalline form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Jun 8, 2021·5 cites·9 claims
- 1096US10562896B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Feb 18, 2020·11 cites·38 claims
- 1196US9394307B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2013·Granted Jul 19, 2016·15 cites·19 claims
- 1296US8906938B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Dec 9, 2014·28 cites·5 claims
- 1395US10660897B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted May 26, 2020·6 cites·5 claims
- 1495US9783540B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2016·Granted Oct 10, 2017·7 cites·45 claims
- 1595US9126939B2C5AR antagonistsFAN PINGCHEN·Filed 2011·Granted Sep 8, 2015·30 cites·4 claims
- 1695US8546408B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationKRASINSKI ANTONI·Filed 2010·Granted Oct 1, 2013·23 cites·11 claims
- 1795US8445515B2C5aR antagonistsFAN PINGCHEN·Filed 2009·Granted May 21, 2013·38 cites·25 claims
- 1895US7718683B2Triazolyl phenyl benzenesulfonamidesCHEMOCENTRYX INC·Filed 2007·Granted May 18, 2010·39 cites·4 claims
- 1994US10683294B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Jun 16, 2020·8 cites·31 claims
- 2094US10464934B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2017·Granted Nov 5, 2019·5 cites·13 claims
- 2194US10329314B2Soluble C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted Jun 25, 2019·12 cites·21 claims
- 2293US11479553B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·24 claims
- 2393US11384079B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 12, 2022·5 cites·18 claims
- 2493US10828285B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Nov 10, 2020·5 cites·27 claims
- 2592US11485737B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·2 cites·29 claims
- 2692US9169261B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Oct 27, 2015·13 cites·26 claims
- 2792US8093247B2Heteroaryl sulfonamides and CCR2UNGASHE SOLOMON·Filed 2009·Granted Jan 10, 2012·18 cites·15 claims
- 2891US11059825B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·2 cites·11 claims
- 2991US10532051B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2015·Granted Jan 14, 2020·6 cites·7 claims
- 3091US8916601B2Aza-aryl 1H-pyrazol-1-YL benzene sulfonamidesCHEMOCENTRYX INC·Filed 2013·Granted Dec 23, 2014·12 cites·20 claims
- 3191US8445518B2Triazolyl pyridyl benzenesulfonamidesCHARVAT TREVOR T·Filed 2010·Granted May 21, 2013·21 cites·23 claims
- 3290US10759807B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Sep 1, 2020·7 cites·38 claims
- 3390US10487098B2Soluble C5aR antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Nov 26, 2019·6 cites·7 claims
- 3489US7777035B2Azaindazole compounds and methods of useCHEMOCENTRYX INC·Filed 2007·Granted Aug 17, 2010·9 cites·10 claims
- 3587US11427541B2Salt forms of a complement component C5A receptorCHEMOCENTRYX INC·Filed 2020·Granted Aug 30, 2022·2 cites·32 claims
- 3687US10208050B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2017·Granted Feb 19, 2019·2 cites·18 claims
- 3786US9783544B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Oct 10, 2017·4 cites·26 claims
- 3885US11254695B2Soluble C5aR antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Feb 22, 2022·1 cites·16 claims
- 3985US10596163B2Aza-aryl 1H-pyrazol-1-yl benzene sulfonamidesCHEMOCENTRYX INC·Filed 2018·Granted Mar 24, 2020·3 cites·19 claims
- 4084US11020394B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2019·Granted Jun 1, 2021·1 cites·8 claims
- 4184US7683176B2Triazolyl pyridyl benzenesulfonamidesCHEMOCENTRYX INC·Filed 2007·Granted Mar 23, 2010·7 cites·18 claims
- 4283US11603356B2Amorphous form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Mar 14, 2023·1 cites·43 claims
- 4383US2023102258A1C5ar antagonistsCHEMOCENTRYX INC·Filed 2022·Application pending·0 cites
- 4482US2025090646A1Methods of treating cancer using heteroaryl-biphenyl amide derivativesCHEMOCENTRYX INC·Filed 2024·Application pending·0 cites
- 4581US10206912B2Heteroaryl sulfonamides and CCR2/CCR9CHEMOCENTRYX INC·Filed 2016·Granted Feb 19, 2019·2 cites·26 claims
- 4681US8288373B2Modulators of CXCR7CHEN XI·Filed 2009·Granted Oct 16, 2012·5 cites·42 claims
- 4780US12371433B2Heteroaryl-biphenyl amines for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2023·Granted Jul 29, 2025·0 cites·13 claims
- 4880US10137120B2Aza-aryl 1H-pyrazol-1-yl benzene sulfonamidesCHEMOCENTRYX INC·Filed 2014·Granted Nov 27, 2018·2 cites·19 claims
- 4979US8343975B24-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidinesZHANG PENGLIE·Filed 2009·Granted Jan 1, 2013·5 cites·4 claims
- 5079US2025346598A1Heteroaryl-biphenyl amines for the treatment of pd-l1 diseasesCHEMOCENTRYX INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 93 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Yibin Zeng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →